Search results for "Riba"
showing 10 items of 371 documents
Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus…
2012
Abstract Half of the patients chronically infected with hepatitis C virus (HCV) genotype 1 fail to respond to pegylated interferon alpha (PEG-IFN) and ribavirin (RBV) therapy. This study assesses the effects of treatment on the evolution of the E1–E2 viral region in non-responder patients infected with HCV-1b. Twenty-three HCV-1b chronically infected patients were studied retrospectively, including 19 non-responders to PEG-IFN/RBV therapy (11 null-responders and 8 relapsers) in the study group, and 4 untreated patients in the control group. Genetic and phylogenetic analyses of the E1–E2 viral populations were performed at baseline and at the time of treatment failure to assess changes in ge…
Mode of selection and experimental evolution of antiviral drugs resistance in vesicular stomatitis virus
2004
Abstract The possession of an antiviral resistance mutation benefits a virus when the corresponding antiviral is present. But does the resistant virus pay a fitness cost when the antiviral is absent? Would an evolutionary history of association between a genotype and a resistance mutation overcome this cost by changes compensating the harmful side-effect of resistance mutations? Are combined therapies more effective against the rise of resistant viruses or against evolutionary compensations? To explore all these questions, we took an experimental evolution approach. After selecting vesicular stomatitis virus (VSV) populations able to replicate under increasing concentrations of ribavirin an…
The role of positive selection in hepatitis C virus
2008
Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 sub…
Tikumu mācība: mācība par vērtībām
1927
Contributor other: Apkalns, Pēteris ( tulkotājs)
Use of Quantitative Morphological Analysis Combined with a Large Sample Size for Estimating Morphological Variability in a Case Study of Armoured Mit…
2015
Abstract The morphology of Oribatida and similar little-known groups of organisms varies considerably, which complicates morphological analysis (e.g. species descriptions). Qualitative analyses have been carried out mostly on a small number of individuals (n < 25). There is lack of studies dealing with mechanisms of how that variation can change in relation to sample size and insufficient discussion on whether qualitative or quantitative analysis is more appropriate for description of morphological variability. A total of 500 adult Carabodes subarcticus Trägårdh, 1902 Oribatida were collected from a local population. Six qualitative and six quantitative traits were characterised using li…
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
2009
ABSTRACTTheir extremely error-prone replication makes RNA viruses targets for lethal mutagenesis. In the case of hepatitis C virus (HCV), the standard treatment includes ribavirin, a base analog with an in vitro mutagenic effect, but the in vivo mode of action of ribavirin remains poorly understood. Here, we test the mutagenic effects of ribavirin plus interferon treatment in vivo using a new method to estimate mutation rates based on the analysis of nonsense mutations. We apply this methodology to a large HCV sequence database containing over 15,000 reverse transcription-PCR molecular clone sequences from 74 patients infected with HCV. We obtained an estimate of the spontaneous mutation ra…
Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.
2001
Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-α or with a combination of IFN-α and ribavirin. The availability of an HCV replicon system (Lohmann et al., Science 285, 110–113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-α inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatme…
Faktiskā kļūda
2017
Bakalaura darba tēma ir “Faktiskā kļūda”. Faktiskā kļūda tradicionāli ir viens no diviem kļūdas institūta veidiem. Latvijas krimināltiesībās kļūdas institūtam nav normatīvais regulējums, kā rezultātā tās saturs tiek atklāts krimināltiesību teorijā. Izvēlētā bakalaura darba tēma ir aktuāla, jo faktiskā kļūda ietekmē personas psihiskās attieksmes veidošanos pret noziedzīgā nodarījuma objektīvajām pazīmēm. Bakalaura darba tēmas ietvaros autore, aplūkojot ārzemju un Latvijas krimināltiesību teorijas nostādnes, izteiks savus secinājumus saistībā ar faktiskās kļūdas saturu un izpratni, kā arī piedāvās piemērus nestandarta faktiskās kļūdas gadījumiem. Atslēgvārdi: Faktiskā kļūda, nodoms, vaina, ap…
Por el comendador, y religiosos del Convento de Nuestra Señora de la Merced de Conso, Extramuros de la Ciudad de Santiago. Con Don Alvaro Sarmiento …
1699
Sig. A-D2, E3 Grav. xil. de la Mare de Déu a la port. Reclams
How to optimize HCV therapy in genotype 1 patients: predictors of response.
2013
The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin (PEG-IFN/RBV) has resulted in a significant improvement in the sustained virological response (SVR) rate and potentially in life years gained compared to dual therapy (DT), when treating naive or treatment-experienced patients with genotype 1 (G1) chronic hepatitis C (CHC). This benefit is partly offset by the increased complexity of treatment, and the increased costs and risks of therapy, making it necessary to optimize the indications for TT. Naive patients with mild fibrosis and the IL28B CC polymorphism and/or with a rapid vi…